Trial Profile
Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2022
Price :
$35
*
At a glance
- Drugs Poloxamer 188 (Primary)
- Indications Sickle cell anaemia; Vaso-occlusive crisis
- Focus Registrational; Therapeutic Use
- Sponsors Mast Therapeutics
- 17 Jun 2014 New trial record
- 05 Mar 2012
- 08 Feb 2012